Literature DB >> 30783917

Mitotic rate as an important prognostic factor in cutaneous malignant melanoma.

A Piñero-Madrona1, G Ruiz-Merino2, P Cerezuela Fuentes3, E Martínez-Barba4, J N Rodríguez-López5, J Cabezas-Herrera5.   

Abstract

BACKGROUND: Recently, the quantification of mitoses in cutaneous melanoma has been discharged from the main prognostic variables of the TNM classification.
OBJECTIVE: To investigate the prognostic value of the presence of mitoses in primary cutaneous melanoma and to establish the number of mitoses per mm2 that may have prognostic significance.
METHODS: A retrospective observational study was performed on 141 patients treated for cutaneous melanoma, who were assessed by the same pathologist, and who had a minimum follow-up of 2 years. Clinical, epidemiological, histopathological and follow-up variables were gathered and compared with the number of mitoses to distinguish the significance of differences by means of univariate, multivariate, and survival analyses.
RESULTS: The cut-off level related to a better sensitivity and specificity was 1.50 mitoses per mm2. The presence of two or more mitoses/mm2 showed a better relationship with prognostic variables and both the overall and disease-free survival than the presence of 1 or more mitoses/mm2. This happens especially in melanomas thicker than 0.8 mm and it could affect the staging in cases with Breslow between 1 and 2 mm.
CONCLUSIONS: A mitotic rate of two or more mitoses per mm2 in cutaneous melanoma should be considered as a more accurate prognostic factor than one or more mitoses per mm2, particularly in tumors equal or greater than 0.8 mm in thickness.

Entities:  

Keywords:  Cut-off; Cutaneous melanoma; Mitosis; Prognostic

Mesh:

Year:  2019        PMID: 30783917     DOI: 10.1007/s12094-019-02064-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  30 in total

1.  Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.

Authors:  John F Thompson; Seng-Jaw Soong; Charles M Balch; Jeffrey E Gershenwald; Shouluan Ding; Daniel G Coit; Keith T Flaherty; Phyllis A Gimotty; Timothy Johnson; Marcella M Johnson; Stanley P Leong; Merrick I Ross; David R Byrd; Natale Cascinelli; Alistair J Cochran; Alexander M Eggermont; Kelly M McMasters; Martin C Mihm; Donald L Morton; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Detection of mitotic figures in thin melanomas--immunohistochemistry does not replace the careful search for mitotic figures in hematoxylin-eosin stain.

Authors:  Karl Ottmann; Michael Tronnier; Christina Mitteldorf
Journal:  J Am Acad Dermatol       Date:  2015-08-13       Impact factor: 11.527

3.  Clinical significance of microscopic melanoma metastases in the nonhottest sentinel lymph nodes.

Authors:  Su Luo; Alice Z C Lobo; Kenneth K Tanabe; Alona Muzikansky; Tyler Durazzo; Arthur Sober; Hensin Tsao; A Benedict Cosimi; Donald P Lawrence; Lyn M Duncan
Journal:  JAMA Surg       Date:  2015-05       Impact factor: 14.766

4.  Impact of the 2009 AJCC staging guidelines for melanoma on the number of mitotic figures reported by dermatopathologists at one institution.

Authors:  Allison R Larson; Brian Rothschild; Andrew C Walls; Scott R Granter; Abrar A Qureshi; George F Murphy; Alvaro C Laga
Journal:  J Cutan Pathol       Date:  2015-05-26       Impact factor: 1.587

5.  Reporting of mitotic rate in cutaneous melanoma: A study using the national cancer data base.

Authors:  Patrick D Lorimer; Emily C Benham; Kendall Walsh; Yimei Han; Meghan R Forster; Terry Sarantou; Richard L White; Joshua S Hill
Journal:  J Surg Oncol       Date:  2017-03       Impact factor: 3.454

6.  Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients.

Authors:  G Ponti; A Pollio; A M Cesinaro; G Pellacani; C Magnoni; S Seidenari
Journal:  Cancer Epidemiol       Date:  2011-12-05       Impact factor: 2.984

7.  How staging of thin melanoma is changed after the introduction of TNM 7th edition: a population-based analysis.

Authors:  A Caldarella; L Fancelli; G Manneschi; A Chiarugi; P Nardini; E Crocetti
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-26       Impact factor: 4.553

8.  The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.

Authors:  Anne Brecht Francken; Helen M Shaw; John F Thompson; Seng-jaw Soong; Neil A Accortt; Manuela F Azzola; Richard A Scolyer; Gerald W Milton; William H McCarthy; Marjorie H Colman; Vincent J McGovern
Journal:  Ann Surg Oncol       Date:  2004-03-15       Impact factor: 5.344

9.  Prediction of survival in patients with thin melanoma: results from a multi-institution study.

Authors:  Andrea Maurichi; Rosalba Miceli; Tiziana Camerini; Luigi Mariani; Roberto Patuzzo; Roberta Ruggeri; Gianfranco Gallino; Elena Tolomio; Gabrina Tragni; Barbara Valeri; Andrea Anichini; Roberta Mortarini; Daniele Moglia; Giovanni Pellacani; Sara Bassoli; Caterina Longo; Pietro Quaglino; Nicola Pimpinelli; Lorenzo Borgognoni; Daniele Bergamaschi; Catherine Harwood; Odysseas Zoras; Mario Santinami
Journal:  J Clin Oncol       Date:  2014-07-07       Impact factor: 44.544

10.  Impact of mitotic activity on the pathological substaging of pT1 cutaneous melanoma.

Authors:  A C de Waal; A S van Harten-Gerritsen; K K H Aben; L A L M Kiemeney; M M van Rossum; W A M Blokx
Journal:  Br J Dermatol       Date:  2014-04       Impact factor: 9.302

View more
  5 in total

1.  Histopathologic synoptic reporting of invasive melanoma: How reliable are the data?

Authors:  Laura A Taylor; Megan M Eguchi; Lisa M Reisch; Andrea C Radick; Hannah Shucard; Kathleen F Kerr; Michael W Piepkorn; Stevan R Knezevich; David E Elder; Raymond L Barnhill; Joann G Elmore
Journal:  Cancer       Date:  2021-05-04       Impact factor: 6.860

2.  Malignant Melanoma: Direct Costs by Clinical and Pathological Profile.

Authors:  Alessandra Buja; Massimo Rugge; Giuseppe De Luca; Manuel Zorzi; Chiara De Toni; Claudia Cozzolino; Antonella Vecchiato; Paolo Del Fiore; Saveria Tropea; Romina Spina; Vincenzo Baldo; Carlo Riccardo Rossi; Simone Mocellin
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-15

3.  Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study.

Authors:  Alessandra Buja; Andrea Bardin; Giovanni Damiani; Manuel Zorzi; Chiara De Toni; Riccardo Fusinato; Romina Spina; Antonella Vecchiato; Paolo Del Fiore; Simone Mocellin; Vincenzo Baldo; Massimo Rugge; Carlo Riccardo Rossi
Journal:  Front Oncol       Date:  2021-11-16       Impact factor: 6.244

Review 4.  The prognostic significance of the clinical and histological parameters in primary cutaneous melanoma patients.

Authors:  Mihaela Antohe; Anastasia Coman; Gabriela Turcu; Roxana Ioana Nedelcu; Alice Brinzea; Mihaela Balaban; Andreea Moroianu; Lorena Manea; Ionela Hulea; Elena Balasescu; Sabina Andrada Zurac; Mirela Cioplea; Cristiana Popp; Luciana Nichita; Daniela Adriana Ion
Journal:  Med Pharm Rep       Date:  2022-07-26

5.  Prognostic significance of regression and mitotic rate in head and neck cutaneous melanoma.

Authors:  Elizabeth Kim; Isaac Obermeyer; Nathan Rubin; Samir S Khariwala
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.